☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | (State or other jurisdiction o ...

Financial Performance - The company reported a net loss of $47.6 million for the year ended December 31, 2022, compared to a net loss of $43.8 million in 2021, resulting in an accumulated deficit of $239.7 million as of December 31, 2022 [226]. - Total revenue for the year ended December 31, 2022, was $43.1 million, representing a 95% increase from $22.1 million in 2021, driven by a $21.5 million increase in retail pharmacy revenue [235]. - The net loss for 2022 was $47.6 million, compared to a net loss of $43.8 million in 2021, indicating a decline of 8.5% in performance [316]. - Operating loss for the year was $46.4 million, which is a 6.7% increase from the operating loss of $43.5 million in the previous year [316]. - The company reported a net cash decrease of $7.97 million for the year ended December 31, 2022, compared to a decrease of $37.9 million in 2021 [322]. Revenue and Growth - Pharmacy and hardware revenue increased by 101% to $42.5 million in 2022, with a significant contribution from volume growth of approximately $13.5 million in Arizona, California, and Michigan [235]. - The pharmacy services business accounted for approximately 97% of the company's total revenues for the year ended December 31, 2022 [331]. - The company expects strong growth in its pharmacy technology segment in 2023 compared to 2022, with historically higher margins than the pharmacy services segment [219]. Expenses and Cost Management - The cost of products sold increased by 86% to $40.5 million in 2022, primarily due to volume growth and increased shipping costs associated with home delivery services [239]. - Pharmacy operations expenses increased by $2.4 million to $15.9 million in 2022, an 18% increase compared to 2021, primarily due to a $1.9 million rise in amortization of intangible assets [244]. - General and administrative expenses rose by approximately $1.2 million to $23.5 million in 2022, a 5% increase from 2021, driven by additional administrative staff and stock-based compensation [247]. - Selling and marketing expenses increased by approximately $1.3 million to $8.5 million in 2022, an 18% increase compared to 2021, mainly due to personnel costs for hiring additional Clinic Account Managers [250]. - Research and development expenses grew by approximately $0.3 million to $1.1 million in 2022, a 31% increase from 2021, reflecting ongoing investment in the MedCenter platform technology [252]. Cash Flow and Financing - Cash used in operating activities increased by $5.1 million to $47.7 million in 2022, a 12% increase compared to 2021 [267]. - Cash provided by financing activities increased by $34.0 million to $42.0 million in 2022, a 430% increase compared to 2021 [269]. - The company completed a private placement in March 2023, raising approximately $16 million to fund restructuring and growth initiatives related to its MedCenter technology business [335]. - The company continues to explore additional financing sources, including stock splits and warrant exercises, to address economic uncertainties and maintain liquidity [264]. Asset and Liability Management - Total current assets decreased to $23.9 million in 2022 from $27.4 million in 2021, a decline of 12.8% [314]. - Cash and cash equivalents dropped to $11.4 million in 2022, down from $19.7 million in 2021, a decrease of 41.5% [314]. - The company's total debt decreased from $9.5 million in 2021 to $4.8 million in 2022, a reduction of approximately 50% [402]. - Total liabilities decreased to $12.3 million in 2022 from $19.1 million in 2021, a reduction of 35.4% [314]. Strategic Initiatives - The company completed the sale of certain pharmacy assets to CVS for an aggregate purchase price of $2.6 million on February 9, 2023, as part of its exit strategy [222]. - The company initiated a reduction in force of approximately 75% of its full-time employees effective January 18, 2023, to preserve capital for its Pharmacy Technology Segment [220]. - The company exited the pharmacy services business in January 2023, resulting in a reduction of approximately 75% of its full-time employees [329]. Tax and Regulatory Considerations - The company has not recognized any income tax expense for the years ended December 31, 2022, and 2021, due to ongoing net income losses [256]. - The company obtained a waiver of any covenant non-compliance or defaults from its lenders for the year ended December 31, 2022 [273]. Market and Economic Factors - The company continuously monitors inflationary pressures that may affect costs, including wages and the price of prescription drugs [277]. - The Company assessed the impact of COVID-19 on its business and financial results, considering various evolving factors as of December 31, 2022 [343].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ Commission File No. 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____ Commission File Number 001-36533 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...